<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3346/jkms.2005.20.6.989</article-id><article-id pub-id-type="pmid">16361810</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Interleukin-10 Promoter Polymorphism is Associated with the Predisposition to the Development of IgA Nephropathy and Focal Segmental Glomerulosclerosis in Korea</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chin</surname><given-names>Ho Jun</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Na</surname><given-names>Ki Young</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Soo Jin</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Kook-Hwan</given-names></name><xref ref-type="aff" rid="A2">*</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Yon Su</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Chun Soo</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Suhnggwon</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chae</surname><given-names>Dong-Wan</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.</aff><aff id="A2"><label>*</label>Department of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.</aff><author-notes><corresp>Address for correspondence: Dong-Wan Chae, M.D. Division of Nephrology, Seoul National University Bundang Hospital, Department of Internal Medicine, Seoul National Univserity College of Medicine, 300 Gumi-dong, Bundang-gu, Seongnam 463-707, Korea. Tel: +82.31-787-7004, Fax: +82.31-787-4052, <email>cdw1302@snubh.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2005</year></pub-date><pub-date pub-type="epub"><day>31</day><month>12</month><year>2005</year></pub-date><volume>20</volume><issue>6</issue><fpage>989</fpage><lpage>993</lpage><history><date date-type="received"><day>22</day><month>2</month><year>2002</year></date><date date-type="accepted"><day>03</day><month>6</month><year>2002</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 The Korean Academy of Medical Sciences</copyright-statement><copyright-year>2005</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The roles of interleukin-10 (IL-10) have been emphasized in several models of glomerulonephritis (GN). Three biallelic polymorphisms within the IL-10 promoter region, at positions -1,082, -819, and -592 from the transcription initiation site, were shown to affect the level of IL-10 production. To investigate the effect of IL-10 promoter polymorphisms on the predisposition to development of GN in Korea, IL-10 promoter polymorphisms were assayed by polymerase chain reaction followed by restriction fragment length polymorphism in 108 patients with IgA nephropathy (IgAN), 49 focal segmental glomerulosclerosis (FSGS), and 100 healthy controls. In comparison with the control, the frequency of -1,082*G alleles were lower in IgAN and the frequencies of -592*C and -819*C were lower in FSGS, respectively. As for the haplotype, GCC haplotype was less frequent among IgAN than the control and ATA haplotype was more frequent among FSGS than the control (<italic>p</italic>&#x0003c;0.05). The frequency of intermediate producer genotypes (GCC/ACC and GCC/ATA) were lower among IgAN or FSGS than the control. Our findings suggested that IL-10 promoter polymorphism predisposed to the development of IgAN and FSGS in Korean patients.</p></abstract><kwd-group><kwd>Glomerulonephritis, IGA</kwd><kwd>Glomerulosclerosis, Focal</kwd><kwd>Polymorphism, Single Nucleotide</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Interleukin-10 (IL-10) is a multifunctional cytokine with diverse effects on the immune response. IL-10 limits inflammation and modulates immune response by inhibiting the production of various pro-inflammatory and Th1 cytokines and blocking the expression of MHC class II and co-stimulatory molecules on the surface of antigen presenting cells and promoting the development of regulatory T cells. On the other hand, IL-10 is a potent cofactor for proliferation of human B cells and affects the B cell differentiation and isotype switching (<xref ref-type="bibr" rid="B1">1</xref>).</p><p>The role of IL-10 in glomerulonephritides (GNs) has been investigated in several studies with conflicting results. The administration of IL-10 (<xref ref-type="bibr" rid="B2">2</xref>), endogenous IL-10 (<xref ref-type="bibr" rid="B3">3</xref>), or IL-10 gene transfer (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>) diminished Th1 response and attenuated glomerular injury in murine crescentic GN initiated by a planted antigen. IL-10 administration also inhibited passive anti-glomerular basement membrane (GBM) GN (<xref ref-type="bibr" rid="B6">6</xref>) and suppressed mesangial cell proliferation in anti-Thy 1 GN in rats (<xref ref-type="bibr" rid="B7">7</xref>). More recently, adenovirus mediated IL-10 transfer had effects on prevention of the development of glomerulosclerosis in FGS/Kist mice model (<xref ref-type="bibr" rid="B8">8</xref>). Yin et al. (<xref ref-type="bibr" rid="B9">9</xref>) reported IL-10 gene deficiency evoked more severe lupus nephritis and higher mortality in murine lupus model. But in other experiments, IL-10 administration induced mesangial cell proliferation with transient reduction of creatinine clearance (<xref ref-type="bibr" rid="B10">10</xref>) and had no protective effects on passive anti-GBM GN in rats (<xref ref-type="bibr" rid="B11">11</xref>). Moreover, IL-10 up-regulated MHC class II expression by rat mesangial cells (<xref ref-type="bibr" rid="B12">12</xref>) and anti-IL-10 antibodies administration diminished the severity of GN in "lupus-prone" mice (<xref ref-type="bibr" rid="B13">13</xref>). In human GN, increase in tubulointerstitial expression of IL-10 was accompanied by nephrotic-range proteinuria (<xref ref-type="bibr" rid="B14">14</xref>). We also observed that the increased intrarenal expression of IL-10 was associated with tubular atrophy and interstitial fibrosis in renal biopsies from patients with IgA nephropathy (<xref ref-type="bibr" rid="B15">15</xref>).</p><p>The gene encoding IL-10 has been mapped to chromosome 1q and several polymorphic sites within the promoter region have recently been described (<xref ref-type="bibr" rid="B16">16</xref>). Three biallelic polymorphisms within the IL-10 promoter region, at positions -1,082, -819, and -592 from the transcription initiation site, have also been identified and one of these polymorphisms, at position -1,082 from the transcription initiation site, was shown to affect the in vitro IL-10 protein production in peripheral blood cells from healthy individuals (<xref ref-type="bibr" rid="B17">17</xref>).</p><p>Based on the aforementioned biological effects of IL-10 and its role in GN, inter-individual differences in the levels of IL-10 production resulting from promoter polymorphism could influence the individual predisposition to several autoimmune diseases, including glomerulonephritides. Increased frequency of the GA/AA genotypes at position -1,082 of the IL-10 promoter was reported in patients with several autoimmune diseases (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>). In fact, IL-10 promoter polymorphism was associated with renal involvement in southern Chinese patients with systemic lupus erythematosus (<xref ref-type="bibr" rid="B20">20</xref>). Low IL-10 producer genotype was more prevalent in Caucasian kidney transplant recipients than in the control population (<xref ref-type="bibr" rid="B21">21</xref>). We also observed a lower frequency of G allele at position -1,082, denoting high IL-10 producer, in Korean kidney transplant recipients compared with the healthy controls (<xref ref-type="bibr" rid="B22">22</xref>). Glomerulonephritis is the most common cause of renal failure in Korean kidney transplant recipients (<xref ref-type="bibr" rid="B23">23</xref>). In addition IgA nephropathy and focal segmental glomerulosclerosis is two most common glomerulonephritis leading to end stage renal failure in Korea. It is therefore possible that IL-10 promoter polymorphisms may be responsible for, at least in part, a portion of the genetic predisposition to glomerulonephritides. The present study was undertaken to investigate the role of these 3 biallelic IL-10 promoter polymorphisms in Korean patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) which were common GNs leading to the end stage renal disease and considered to have different pathogenetic mechanism apart from each other.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Patients and control subject</title><p>Patients were recruited from the Department of Internal Medicine, Kangdong Sacred Heart Hospital, and Seoul National University Hospital in Seoul, Korea. One hundred and eight patients with primary IgAN and forty nine patients with primary FSGS who provided informed consent, were enrolled in this study. The diagnosis of IgAN and FSGS was based on the typical light, immunofluorescent, and electron microscopic changes on a renal biopsy. Patients with the evidences of systemic diseases such as diabetes, chronic liver disease, and systemic lupus erythematosus were excluded. One hundred randomly selected subjects who had no evidence of renal disease and were normotensive were also recruited from the Health Promotion Center of the same hospitals as controls. The Institutional Review Board of two institutions approved the research protocol used for this study.</p></sec><sec><title>Extraction of genomic DNA and genotype determination</title><p>Genomic DNA was extracted from the buffy coat using commercial DNA isolation kit (Qiagen, Germany). The 3 biallelic IL-10 promoter polymorphisms were detected by PCR amplification followed by restriction enzyme digestion basically as described previously (<xref ref-type="bibr" rid="B24">24</xref>). Briefly, the DNA fragment containing the position -592 was amplified in 50 &#x000b5;L reaction mixture containing 500 ng of template DNA, 0.5 &#x000b5;M of of each primer, 1.5 mM of MgCl<sub>2</sub>, 200 &#x000b5;M each of dGTP, dATP, dTTP and dCTP, 2.5 unit of <italic>Taq</italic> polymerase (Promega, Medison WI, U.S.A.) and <italic>Taq</italic> polymerase buffer. Amplification of the fragment around -592 was performed under the same condition except that a final concentration of 2 mM MgCl<sub>2</sub> was used. Amplification of fragment around -1,082 was performed using HotStarTaq kit (Qiagen, Germany), and Q-solution was included in the PCR reaction mixture. Primers used were as follows: for the amplification of -592 fragment, sense primer 5'gtgttcctaggtcacagtga, antisense primer 5'gtcatggtgagcactacctga 3'; for -819, sense primer 5'tcattctatgtgctggagatg 3', antisense primer 5'tgggggaagtgggtaagagt 3'; for -1,082, sense primer 5'ctcgctgcaacccaactggc 3', antisense primer 5'tcttacgcaacccaactggc 3'. PCR was performed using Perkin Elmer Cetus thermocycler under the following cycling parameters: denaturation at 94&#x02103; for 2 min, followed by 35 cycles of denaturation at 94&#x02103; for 30 sec; annealing at 60&#x02103; for 45 sec; and extension at 72&#x02103; for 1 min. This was followed by final extension at 72&#x02103; for 10 min. For amplification of the -1,082, an initial activation step of 95&#x02103; for 15 min preceded the cycling program. The two alleles at each polymorphic site was identified by incubating 15 &#x000b5;L aliquot of the PCR product with specific restriction enzyme, followed by electrophoresis on 3% agarose gels. Restriction enzyme RsaI cut the fragment at the position -592 when allele A was present, giving rise to 176 and 236 bp fragments. In the presence of allele C in -819 fragment, 125 and 84 bp fragments were generated by digestion with <italic>Mae</italic>III. <italic>Mnl</italic> I cut -1082 fragment when allele G was present to generate 106 and 33 bp fragments. The results of this restriction fragment length polymorphism assay were confirmed by direct sequencing of the promoter region of the IL-10 gene in 10% of patients and controls (Macrogen Inc., Seoul, Korea).</p></sec><sec><title>Statistical analysis</title><p>All data were analyzed using the SPSS version 10.0. The chi-square test was used for detecting differences in the genotype distribution of the patients and controls. Odd ratio for individuals with a specific genotype to develop GN was estimated by Mantel-Haenszel test. A <italic>p</italic>-value that was less than 0.05 was considered to be statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Allele frequencies of IL-10 promoter</title><p>Frequencies of the alleles of IL-10 promoter in our patients and controls were summarized in <xref ref-type="table" rid="T1">Table 1</xref>. For comparison, reported allele frequencies from southern Chinese (<xref ref-type="bibr" rid="B20">20</xref>) and U.K. white population (<xref ref-type="bibr" rid="B25">25</xref>) were also included. The polymorphisms at -592 and -819 bp were found to be in complete linkage disequilibrium. This meant that individuals with A allele at -592 bp also had T allele at -819 bp, whereas those with C allele at -592 bp also had C allele at -819 bp. The allele frequencies of our controls were very similar to those of Chinese population but markedly different from U.K. population. To point out, the frequency of G allele at position -1,082 was markedly lower among our controls than the U.K. population.</p><p>For IgAN patients, the frequency of G allele at position -1,082 was even significantly lower than the control (<italic>p</italic>=0.006). For FSGS, the frequency of C allele at position -592 or at position -819 was significantly lower than the control (<italic>p</italic>=0.026).</p></sec><sec><title>Haplotype frequencies of IL-10 promoter</title><p>Three haplotypes were identified: GCC, ACC and ATA for the -1,082, -819 and -592 polymorphisms, respectively. The frequencies of the haplotypes of IL-10 promoter in IgAN, FSGS patients and controls were summarized in <xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="table" rid="T3">3</xref>.</p><p>There was a statistically significant difference in the frequency of GCC haplotype between IgAN and control. That is, IgAN patients were less likely to carry GCC haplotype than normal controls (0.028 vs. 0.095, <italic>p</italic>=0.006). FSGS patients were less likely to carry GCC haplotype than controls, although this did not reach a statistical significance (0.031 vs. 0.095). Besides, FSGS patients had a higher frequency of ATA haplotype than normal control (0.755 vs. 0.620, <italic>p</italic>=0.026).</p></sec><sec><title>Genotype frequencies of IL-10 promoter</title><p>From our subjects, we observed five genotypic combinations of the three haplotypes: GCC/ACC, GCC/ATA, ACC/ACC, ACC/ATA and ATA/ATA. No GCC homozygous subjects were observed from our study (<xref ref-type="table" rid="T4">Table 4</xref>).</p><p>No patients among the IgAN and FSGS group carried GCC/ACC genotype, while 8 (8%) among normal control group carried this genotype. This marked a statistical difference either between IgAN and control (<italic>p</italic>=0.002) or between FSGS and control group (<italic>p</italic>=0.049). There was no significant difference in the frequency of GCC/ATA genotype either between IgAN and control group or between FSGS and control group. However, as for the genotypic frequency of intermediate producer as a whole (i.e., GCC/ACC and GCC/ATA genotypes), there was a significant difference either between IgAN and control (<italic>p</italic>=0.005) or between FSGS and control group (<italic>p</italic>=0.048).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Three biallelic polymorphisms at positions -1,082(G/A), -819 (A/T) and -592 (A/C) of IL-10 promoter region are generally known to produce three haplotypes: GCC, ATA and ACC. Such allelic or haplotypic difference correlated with the difference in in vitro IL-10 production after various immunological stimuli. Even though not confirmed in recent study (<xref ref-type="bibr" rid="B26">26</xref>), Turner et al. reported that the presence of -1,082*A allele was associated with lower production of IL-10 by mitogen-stimulated peripheral blood leukocyte (<xref ref-type="bibr" rid="B17">17</xref>). In addition, the -592*A allele was associated with a reduced IL-10 production by peripheral blood mononuclear cell in the presence of IFN-&#x003b3; (<xref ref-type="bibr" rid="B27">27</xref>). Some authors classify IL-10 haplotypic variations into high, intermediate and low producers (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). GCC homozygous patients were considered as high producers (i.e., GCC/GCC genotype), GCC heterozygous patients as intermediate producers (i.e., GCC/ACC and GCC/ATA genotypes) and GCC negative patients as low producers (i.e., ATA/ATA, ACC/ATA and ACC/ACC genotypes)</p><p>In this study, we analyzed the polymorphic frequencies of the IL-10 promoter regions in Korean patients with IgAN and FSGS. We found that the distribution of alleles of IL-10 promoter in Korean healthy population is very similar to those in southern China population, but markedly different from Caucasian, which is consistent with the previous reports (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). Characteristically, none of our controls and patients have the -1082*GG genotype or GCC/GCC genotype. This might mean that there was no one with "high IL-10 producing" phenotype among our subjects-either among the GN patients or among the healthy control.</p><p>The frequencies of -1,082*G alleles, which were reported to be related with a higher IL-10 production (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B27">27</xref>), were lower in patients with IgAN than healthy controls. The frequencies of -819*C and -592*C, which are also known to represent a high producer, were also lower among FSGS than the control (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p>With respect to the haplotypes (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="table" rid="T3">3</xref>), there was a lower frequency of GCC haplotype among IgAN patients than the control (<italic>p</italic>=0.006, OR=0.27, CI [0.11-0.70]). FSGS patients were also less likely to carry the GCC haplotype, although not reached a statistical significance. ATA haplotype, which is known to represent a low producer, was more frequent among FSGS than control (<italic>p</italic>=0.026, OR=1.89, CI [1.09-3.25]).</p><p>Such genetic difference is more pronounced in terms of the genotype (<xref ref-type="table" rid="T4">Table 4</xref>). None of our IgAN or FSGS group carried the GCC/ACC genotype, which marked a stark difference in comparison with the control group with 8% frequency of the GCC/ACC genotype. Such statistical difference still holds in terms of the intermediate producer group, GCC/ACC and GCC/ATA genotypes, as a whole. Collectively, these findings might mean that the lower level of IL-10 production resulting from IL-10 promoter polymorphism predisposes individuals to the development of IgAN and FSGS.</p><p>Our findings are very similar to the study of Mok et al. (<xref ref-type="bibr" rid="B20">20</xref>) who demonstrated lower frequencies of -579*CC/-824*CC genotype and non-ATA haplotype in SLE patients with renal involvement. It was very interesting to note that IL-10 promoter polymorphisms predispose individuals to 3 different GNs, IgAN, FSGS, and lupus nephritis, which have an independent immunological pathogenesis. In addition, the frequency of -1,082*AA genotype was more prevalent in Caucacian kidney transplant recipient than in control group (<xref ref-type="bibr" rid="B21">21</xref>). In our 185 kidney transplant recipients, the frequencies of -592*CC/-819*CC and -1082*GA genotype were 9.2% and 5.9% respectively, which were lower than in controls (<xref ref-type="bibr" rid="B22">22</xref>). In this regard, it might be worthwhile to investigate the role of IL-10 promoter polymorphism in other nephropathies such as membranous GN, membranoproliferative GN and even diabetic nephropathy which are common causes of end stage renal disease.</p><p>The biological effects of IL-10 and the role of IL-10 in GN is very complex and is beyond the scope of our discussion. From the results of the present study, it may be speculative that IL-10 limits inflammation and modulates injuries to kidney initiated by various different mechanisms. In this respect, IL-10 may play an important role in the process of progression common to both IgA nephropathy and FSGS. Recently IL-10 high producer genotype was reported to be associated with slower progression of IgA nephropathy and FSGS in Caucasian patients (<xref ref-type="bibr" rid="B30">30</xref>). Because our study was a cross-sectional study with a great variability in follow-up duration and patient characteristics affecting the progression of glomerulonephritis, we could not analysis the association of IL-10 gene polymorphism and progression of diseases. Well-designed prospective long-term study will be necessary to evaluate the role of IL-10 in the progression of various primary and secondary glomerular diseases having different mechanisms of pathogenesis such as IgA nephroapthy, FSGS, membranous nephropathy, lupus nephritis, and diabetic nephropathy.</p><p>Finally, a cytokine works in the context of "networks of cytokines" i.e. many cytokines influence each other. The role of gene polymorphisms of various cytokines other than IL-10 in GN has been reported (<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B33">33</xref>) and allelic distributions in cytokine gene polymorphisms varied according to the ethnic groups (<xref ref-type="bibr" rid="B25">25</xref>). In this context, it might be necessary to examine our observation as to the effect of IL-10 promoter gene polymorphism on the development of GN in different ethnic populations.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>This research was supported by the <funding-source>Hallym Academy of Science</funding-source>, at Hallym University (2000), Korea.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>KW</given-names></name><name><surname>de Waal Malefyt</surname><given-names>R</given-names></name><name><surname>Coffman</surname><given-names>RL</given-names></name><name><surname>O'Garra</surname><given-names>A</given-names></name></person-group><article-title>Interleukin-10 and the interleukin-10 receptor</article-title><source>Annu Rev Immunol</source><year>2001</year><volume>19</volume><fpage>683</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">11244051</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tipping</surname><given-names>PG</given-names></name><name><surname>Kitching</surname><given-names>AR</given-names></name><name><surname>Huang</surname><given-names>XR</given-names></name><name><surname>Mutch</surname><given-names>DA</given-names></name><name><surname>Holdworth</surname><given-names>SR</given-names></name></person-group><article-title>Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis</article-title><source>Eur J Immunol</source><year>1997</year><volume>27</volume><fpage>530</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">9045927</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitching</surname><given-names>AR</given-names></name><name><surname>Tipping</surname><given-names>PG</given-names></name><name><surname>Timoshanko</surname><given-names>JR</given-names></name><name><surname>Holdsworth</surname><given-names>SR</given-names></name></person-group><article-title>Endogenous interleukin-10 regulates Th1 response that induce crescentic glomerulonephritis</article-title><source>Kidney Int</source><year>2002</year><volume>57</volume><fpage>518</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">10652028</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Shemi</surname><given-names>AG</given-names></name><name><surname>Fujinaka</surname><given-names>H</given-names></name><name><surname>Matsuki</surname><given-names>A</given-names></name><name><surname>Kamiie</surname><given-names>J</given-names></name><name><surname>Kovalenko</surname><given-names>P</given-names></name><name><surname>Qu</surname><given-names>Z</given-names></name><name><surname>Bilim</surname><given-names>V</given-names></name><name><surname>Nishimoto</surname><given-names>G</given-names></name><name><surname>Yaoita</surname><given-names>E</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Anegon</surname><given-names>I</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name></person-group><article-title>Suppression of experimental crescentic glomerulonephritis by interleukin-10 gene transfer</article-title><source>Kidney Int</source><year>2004</year><volume>65</volume><fpage>1280</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">15086467</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuchi</surname><given-names>N</given-names></name><name><surname>Maruyama</surname><given-names>H</given-names></name><name><surname>Kuroda</surname><given-names>T</given-names></name><name><surname>Kameda</surname><given-names>S</given-names></name><name><surname>Iino</surname><given-names>N</given-names></name><name><surname>Kawachi</surname><given-names>H</given-names></name><name><surname>Nishikawa</surname><given-names>Y</given-names></name><name><surname>Hanawa</surname><given-names>H</given-names></name><name><surname>Tahara</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>J</given-names></name><name><surname>Gejyo</surname><given-names>F</given-names></name></person-group><article-title>Hydrodynamics-based delivery of the viral interleukin-10 gene suppresses experimental crescentic glomerulonephritis in Wistar-Kyoto rats</article-title><source>Gene Ther</source><year>2003</year><volume>10</volume><fpage>1297</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">12883526</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>XR</given-names></name><name><surname>Kitching</surname><given-names>AR</given-names></name><name><surname>Tipping</surname><given-names>PG</given-names></name><name><surname>Holdworth</surname><given-names>SR</given-names></name></person-group><article-title>Interleukin-10 inhibits macrophage-induced glomerular injury</article-title><source>J Am Soc Nephrol</source><year>2000</year><volume>11</volume><fpage>262</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">10665933</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitching</surname><given-names>AR</given-names></name><name><surname>Katerelos</surname><given-names>M</given-names></name><name><surname>Mudge</surname><given-names>SJ</given-names></name><name><surname>Tipping</surname><given-names>PG</given-names></name><name><surname>Power</surname><given-names>DA</given-names></name><name><surname>Holdsworth</surname><given-names>SR</given-names></name></person-group><article-title>Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis</article-title><source>Clin Exp Immunol</source><year>2002</year><volume>128</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11982588</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YK</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><name><surname>Paik</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>YI</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name></person-group><article-title>Suppression of glomerulosclerosis by adenovirus-mediated IL-10 expression in the kidney</article-title><source>Gene Ther</source><year>2003</year><volume>10</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">12646861</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Bahtiyar</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Robert</surname><given-names>ME</given-names></name><name><surname>McNiff</surname><given-names>J</given-names></name><name><surname>Madaio</surname><given-names>MP</given-names></name><name><surname>Craft</surname><given-names>J</given-names></name></person-group><article-title>IL-10 regulates murine lupus</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>2148</fpage><lpage>2155</lpage><pub-id pub-id-type="pmid">12165544</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadban</surname><given-names>SJ</given-names></name><name><surname>Tesch</surname><given-names>GH</given-names></name><name><surname>Foti</surname><given-names>R</given-names></name><name><surname>Atkins</surname><given-names>RC</given-names></name><name><surname>Nikolic-Paterson</surname><given-names>DJ</given-names></name></person-group><article-title>Interleukin-10 is a mesangial cell growth factor in vitro and in vivo</article-title><source>Lab Invest</source><year>1997</year><volume>76</volume><fpage>619</fpage><lpage>627</lpage><pub-id pub-id-type="pmid">9166281</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadban</surname><given-names>SJ</given-names></name><name><surname>Tesch</surname><given-names>GH</given-names></name><name><surname>Lan</surname><given-names>HY</given-names></name><name><surname>Atkins</surname><given-names>RC</given-names></name><name><surname>Nikolic-Paterson</surname><given-names>DJ</given-names></name></person-group><article-title>Effect of interleukin-10 treatment on crescentic glomerulonephritis in rats</article-title><source>Kidney Int</source><year>1997</year><volume>51</volume><fpage>1809</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">9186870</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadban</surname><given-names>SJ</given-names></name><name><surname>Tesch</surname><given-names>GH</given-names></name><name><surname>Foti</surname><given-names>R</given-names></name><name><surname>Lan</surname><given-names>HY</given-names></name><name><surname>Atkins</surname><given-names>RC</given-names></name><name><surname>Nikolic-Paterson</surname><given-names>DJ</given-names></name></person-group><article-title>Interleukin-10 differentially modulates MHC class II expression by mesangial cells and macrophages in vitro and in vivo</article-title><source>Immunology</source><year>1998</year><volume>94</volume><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">9708189</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>H</given-names></name><name><surname>Muchamuel</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name><name><surname>Andrade</surname><given-names>S</given-names></name><name><surname>Menon</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>M</given-names></name></person-group><article-title>Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice</article-title><source>J Exp Med</source><year>1994</year><volume>179</volume><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">8270873</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niemir</surname><given-names>ZI</given-names></name><name><surname>Ondracek</surname><given-names>M</given-names></name><name><surname>Dworacki</surname><given-names>G</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Waldherr</surname><given-names>R</given-names></name><name><surname>Ritz</surname><given-names>E</given-names></name><name><surname>Otto</surname><given-names>HF</given-names></name></person-group><article-title>In situ upregulation of IL-10 reflects the activity of human glomerulonephritides</article-title><source>Am J Kidney Dis</source><year>1998</year><volume>32</volume><fpage>80</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">9669428</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>CS</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Ahn</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Chae</surname><given-names>DW</given-names></name><name><surname>Koo</surname><given-names>JR</given-names></name><name><surname>Chun</surname><given-names>RW</given-names></name><name><surname>Noh</surname><given-names>JW</given-names></name></person-group><article-title>Th1/Th2 predominance and proinflammatory cytokines determine the clinicopathological severity of IgA nephroapathy</article-title><source>Nephrol Dial Transplant</source><year>2001</year><volume>16</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">11158399</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eskdale</surname><given-names>J</given-names></name><name><surname>Kube</surname><given-names>D</given-names></name><name><surname>Tesch</surname><given-names>H</given-names></name><name><surname>Gallagher</surname><given-names>G</given-names></name></person-group><article-title>Mapping of the human IL-10 gene and further characterization of the 5'flanking sequence</article-title><source>Immunogenetics</source><year>1997</year><volume>46</volume><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">9162098</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>DM</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name><name><surname>Sankaran</surname><given-names>D</given-names></name><name><surname>Lazarus</surname><given-names>M</given-names></name><name><surname>Sinnott</surname><given-names>PJ</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><article-title>An investigation of poplymorphism in the interleukin-10 gene promoter</article-title><source>Eur J Immunogenet</source><year>1997</year><volume>24</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9043871</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagore</surname><given-names>A</given-names></name><name><surname>Gonsalkorale</surname><given-names>WM</given-names></name><name><surname>Pravica</surname><given-names>V</given-names></name><name><surname>Hajeer</surname><given-names>AH</given-names></name><name><surname>McMahon</surname><given-names>R</given-names></name><name><surname>Whorwell</surname><given-names>PJ</given-names></name><name><surname>Sinnott</surname><given-names>PJ</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><article-title>Interleukin-10 (IL-10) genotypes in inflammatory bowel disease</article-title><source>Tissue Antigens</source><year>1999</year><volume>54</volume><fpage>386</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">10551422</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajeer</surname><given-names>AH</given-names></name><name><surname>Lazarus</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Mageed</surname><given-names>RA</given-names></name><name><surname>Vencovsky</surname><given-names>J</given-names></name><name><surname>Sinnott</surname><given-names>P</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name><name><surname>Ollier</surname><given-names>WE</given-names></name></person-group><article-title>IL-10 gene promoter polymorphisms in rheumatoid arthritis</article-title><source>Scand J Rheumatol</source><year>1998</year><volume>27</volume><fpage>142</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">9572641</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Lanchbury</surname><given-names>JS</given-names></name><name><surname>Chan</surname><given-names>DW</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name></person-group><article-title>Interleukin-10 promoter polymorphisms in southern Chinese patients with systemic lupus erythematosus</article-title><source>Arthritis Rheum</source><year>1998</year><volume>41</volume><fpage>1090</fpage><lpage>1095</lpage><pub-id pub-id-type="pmid">9627019</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sankaran</surname><given-names>D</given-names></name><name><surname>Asderakis</surname><given-names>A</given-names></name><name><surname>Ashraf</surname><given-names>S</given-names></name><name><surname>Roberts</surname><given-names>IS</given-names></name><name><surname>Short</surname><given-names>CD</given-names></name><name><surname>Dyer</surname><given-names>PA</given-names></name><name><surname>Sinnott</surname><given-names>PJ</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><article-title>Cytokine gene polymorphisms predict acute graft rejection following renal transplantation</article-title><source>Kidney Int</source><year>1999</year><volume>56</volume><fpage>281</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">10411704</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>KJ</given-names></name><name><surname>Song</surname><given-names>YR</given-names></name><name><surname>Chae</surname><given-names>D-W</given-names></name><name><surname>Oh</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Noh</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>YK</given-names></name><name><surname>Lim</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name></person-group><article-title>The impact of gene polymorphism of interleulin-10 and interferon-gamma on the clinical courses of renal transplant patients in Korea</article-title><source>Korean J Nephrol</source><year>2002</year><volume>21</volume><fpage>990</fpage><lpage>999</lpage></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JP</given-names></name><name><surname>Ro</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>JS</given-names></name><name><surname>Ha</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Chae</surname><given-names>DW</given-names></name><name><surname>Ahn</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name></person-group><article-title>Single center study about post-transplant anemia (PTA) in Korean transplant recipients: prevalence and risk factors for PTA</article-title><source>J Korean Soc Transplant</source><year>2004</year><volume>18</volume><fpage>144</fpage><lpage>154</lpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards-Smith</surname><given-names>CJ</given-names></name><name><surname>Jonsson</surname><given-names>JR</given-names></name><name><surname>Purdie</surname><given-names>DM</given-names></name><name><surname>Bansal</surname><given-names>A</given-names></name><name><surname>Shorthouse</surname><given-names>C</given-names></name><name><surname>Powell</surname><given-names>EE</given-names></name></person-group><article-title>Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa</article-title><source>Hepatology</source><year>1999</year><volume>30</volume><fpage>526</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">10421663</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynard</surname><given-names>MP</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Navarrete</surname><given-names>CV</given-names></name></person-group><article-title>Allele frequencies of polymorphisms of the tumor necrosis factor-&#x003b1;, interleukin-10, interferon-&#x003b3; and interleukin-2 genes in a North European Caucasoid group from the UK</article-title><source>Eur J Immunogenet</source><year>2000</year><volume>27</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">10998089</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartwright</surname><given-names>NH</given-names></name><name><surname>Keen</surname><given-names>LJ</given-names></name><name><surname>Demaine</surname><given-names>AG</given-names></name><name><surname>Hurlock</surname><given-names>NJ</given-names></name><name><surname>McGonigle</surname><given-names>RJ</given-names></name><name><surname>Rowe</surname><given-names>PA</given-names></name><name><surname>Shaw</surname><given-names>JF</given-names></name><name><surname>Szydlo</surname><given-names>RM</given-names></name><name><surname>Kaminski</surname><given-names>ER</given-names></name></person-group><article-title>A study of cytokine gene polymorphisms and protein secretion in renal transplantation</article-title><source>Transpl Immunol</source><year>2001</year><volume>8</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">11316066</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenwasser</surname><given-names>LJ</given-names></name><name><surname>Borish</surname><given-names>L</given-names></name></person-group><article-title>Genetics of atopy and asthma: The rationale behind promoter-based candidate gene studies (IL-4 and IL-10)</article-title><source>Am J Respir Crit Care Med</source><year>1997</year><volume>156</volume><fpage>S152</fpage><lpage>S155</lpage><pub-id pub-id-type="pmid">9351597</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrey</surname><given-names>C</given-names></name><name><surname>Pravica</surname><given-names>V</given-names></name><name><surname>Sinnott</surname><given-names>PJ</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><article-title>Genotyping for polymorphisms in interferon-&#x003b3;, interleukin-10, transforming growth factor-&#x003b2;1 and tumor necrosis factor-&#x003b1; genes: a technical report</article-title><source>Transpl Immunol</source><year>1998</year><volume>6</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">9848226</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>DM</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name><name><surname>Sankarah</surname><given-names>D</given-names></name><name><surname>Lazarus</surname><given-names>M</given-names></name><name><surname>Sinnot</surname><given-names>PJ</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name></person-group><article-title>An investigation of polymorphism in the interleukin-10 gene promoter</article-title><source>Eur J Immunogenet</source><year>1997</year><volume>24</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9043871</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bantis</surname><given-names>C</given-names></name><name><surname>Heerring</surname><given-names>PJ</given-names></name><name><surname>Aker</surname><given-names>S</given-names></name><name><surname>Klein-Vehne</surname><given-names>N</given-names></name><name><surname>Grabensee</surname><given-names>B</given-names></name><name><surname>Ivens</surname><given-names>K</given-names></name></person-group><article-title>Association of interleukin-10 gene G-1082A polymorphism with the progression of primary glomerulonephritis</article-title><source>Kideny Int</source><year>2004</year><volume>66</volume><fpage>288</fpage><lpage>294</lpage></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medcraft</surname><given-names>J</given-names></name><name><surname>Hitman</surname><given-names>GA</given-names></name><name><surname>Sachs</surname><given-names>JA</given-names></name><name><surname>Whichelow</surname><given-names>CE</given-names></name><name><surname>Raafat</surname><given-names>I</given-names></name><name><surname>Moore</surname><given-names>RH</given-names></name></person-group><article-title>Autoimmune renal disease and tumor necrosis factor beta gene polymorphism</article-title><source>Clin Nephrol</source><year>1993</year><volume>40</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">8222374</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>BI</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Spray</surname><given-names>BJ</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Rothschild</surname><given-names>CB</given-names></name><name><surname>Bowden</surname><given-names>DW</given-names></name></person-group><article-title>Genetic linkage analysis of growth factor loci and end-stage renal disease in African Americans</article-title><source>Kidney Int</source><year>1997</year><volume>51</volume><fpage>819</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">9067916</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Cheng</surname><given-names>CH</given-names></name><name><surname>Wu</surname><given-names>MJ</given-names></name><name><surname>Lian</surname><given-names>JD</given-names></name></person-group><article-title>Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy</article-title><source>Kidney Int</source><year>2000</year><volume>58</volume><fpage>783</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">10916103</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Allele frequencies of the interleukin-10 promoter region among Korean patients and controls and southern Chinese and U.K. white population</p></caption><graphic xlink:href="jkms-20-989-i001"/><table-wrap-foot><fn><p><sup>*</sup><italic>p</italic>=0.026 vs. control, <sup>&#x02020;</sup><italic>p</italic>=0.006 vs. control.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Haplotype distribution of IL-10 promoter gene in IgAN patients and healthy control</p></caption><graphic xlink:href="jkms-20-989-i002"/><table-wrap-foot><fn><p><sup>*</sup><italic>p</italic>=0.006 vs. healthy controls.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Haplotype distribution of IL-10 promoter gene in FSGS patients and healthy control</p></caption><graphic xlink:href="jkms-20-989-i003"/><table-wrap-foot><fn><p><sup>*</sup><italic>p</italic>=0.026 vs. healthy controls.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>IL-10 genotype frequencies in healthy controls, IgAN and FSGS</p></caption><graphic xlink:href="jkms-20-989-i004"/><table-wrap-foot><fn><p><sup>*</sup><italic>p</italic>=0.002 vs. healthy control, <sup>&#x02020;</sup><italic>p</italic>=0.049 vs. healthy control, <sup>&#x02021;</sup><italic>p</italic>=0.005 vs. healthy control, <sup>&#x000a7;</sup><italic>p</italic>=0.048 vs. healthy control.</p></fn></table-wrap-foot></table-wrap></floats-group></article>